Project Grant R44CA268466
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University provides $158,899 to establish an innovative platform for simultaneous intensity, energy modulation, and compensation (SIEMAC) optimization. This will enable conformal flash proton therapy for the treatment of central lung cancer, which aims to reduce toxicity to organs at risk while maintaining tumor control. The grant also supports the development of a quality assurance...
- Radiabeam Systems, LLC received a $199,597 Project Grant award from the Department of Energy Office of Science on June 28, 2021 to support development of a tunable electronic brachytherapy system. The award was made under the Office of Science Financial Assistance Program (CFDA 81.049), which aims to deliver scientific discoveries and tools to transform understanding of nature and advance U.S. energy and economic security. The grant funded Radiabeam Systems to develop a brachytherapy device that...
- This federal Project Grant award of $695,814 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research to develop artificial intelligence (AI) technologies that enable online adaptive radiation therapy for proton therapy. The key products and services to be delivered through this grant include: 1) Developing an asymmetric autoencoder network...
- The federal Project Grant award of $1,148,652 was made on April 1, 2025 by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant supports research and development of an ultra-high spatial resolution photon-counting computed tomography (CT) system with multiple focal spots. The key products to be delivered include: Developing system models and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to M3D, Inc. will develop a novel gamma-ray radiation imager for image-guided tumor diagnostics. The goal is to create a system capable of rapidly and accurately detecting gamma-ray emitting radiotracers used to identify the location of lymph nodes and tumor drainage during cancer surgical procedures. The project will characterize the design parameters of the...
- This $391,764 federal Project Grant awarded by the National Science Foundation (CFDA 47.041 - Engineering) to Purdue University will fund the development of a laser-based "cell radar speed gun" to measure the speed of cancer cells crawling through living tissue and the speed of immune cells patrolling tumors. The goal is to use this biodynamic imaging technology to assess the effectiveness of cancer immunotherapies for individual patients. The award will also extend biodynamic...
- This Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) will support the development of an ultrasonically-enhanced swept source optical coherence tomography (UESS-OCT) system for label-free, non-invasive optical imaging inside the human body. The $425,000 award to the Regents of the University of California at Riverside will fund research to utilize ultrasound waves to focus and steer light through tissue, enabling high-resolution structural and...
- The National Cancer Institute awarded a $984,830 Project Grant to EF Therapeutics Corp. under the Cancer Treatment Research federal grant program (CFDA 93.395). The goal of this 2-year project is to validate and translate the use of gene electrotransfer (GET) with EF Therapeutics' novel IntelliPULSE platform technology to enhance non-viral gene delivery for immunotherapy of solid tumors. The project aims to develop and commercialize next-generation technologies that can be used to administer...
- This Project Grant award, titled "ULTRAFAST OPTICAL BRAIN IMAGING VIA BLURRED MATRIX COMPLETION", is funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The $682,299 award will support research and development of a new computational imaging approach to enable high-speed, large-area brain imaging. This technology aims to transform the...
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
ULTRA-FAST IMAGING FOR THE SAFE DELIVERY OF ELECTRON FLASH RADIATION THERAPY - ABSTRACT RADIATION THERAPY IS A SUPPLEMENTARY CURATIVE TREATMENT USED ADJUVANT WITH MOST SURGERY AND CHEMOTHERAPY, BEING DELIVERED TO NEARLY 1 OUT OF EVERY 4 PEOPLE IN THEIR LIFETIME. WHILE IMAGE GUIDANCE AND CONFORMAL PLANNING REDUCED THE DOSE TO HEALTHY TISSUE, THERE IS STILL A SUBSTANTIAL RISK OF TISSUE DAMAGE THAT SETS THE UPPER LIMIT OF DOSE DEPOSITED TO THE TUMOR. RECENTLY THE MINIMIZATION OF HEALTHY TISSUE DAMAGE WAS DEMONSTRATED TO OCCUR WHEN ULTRA-HIGH DOSE RATES (UHDR) WERE USED FOR IRRADIATION, KNOWN AS THE FLASH EFFECT. UHDR ARE DEFINED AS A COMPLEX SET OF HIGH AVERAGE DOSE RATES (>40 GY/S), INSTANTANEOUS DOSE RATES (>106 GY/S), TOTAL DOSE VALUES (>8GY) AND TEMPORAL PULSE STRUCTURES. FLASH PROMISES A REDUCTION IN NORMAL TISSUE TOXICITY BY 20-50% AND OUR CLINICAL SITE PARTNER DARTMOUTH-HITCHCOCK, HAS BEEN THE FIRST TO DEMONSTRATE ROUTINE WEEKLY DELIVERY OF FLASH ON A CLINICALLY USED LINAC. THIS MODIFICATION SHOWS ENORMOUS TRANSLATIONAL POTENTIAL TO DELIVER ELECTRON FLASH (EFLASH) IN ANY RADIOTHERAPY CENTER USING EXISTING SYSTEMS. HOWEVER, WHILE MOST RESEARCH IN THE FIELD IS FOCUSED ON ELUCIDATING THE RADIOBIOLOGICAL MECHANISMS OF FLASH, WORK TOWARDS MITIGATING THE RISKS OF FLASH IS LARGELY UNTOUCHED, YET WILL BE PIVOTAL FOR WIDER CLINICAL IMPLEMENTATION. NEW TECHNIQUES FOR DETECTION MONITORING OF RADIATION NEED TO BE DEVELOPED DUE TO THE MILLISECOND TIMESCALES AT WHICH FLASH OPERATES WHICH MAKE TRADITIONAL METHODS UNSUITABLE. IN THIS PROJECT, WE HAVE LEVERAGED OUR CAMERA PLATFORM, BEAMSITE, THE WORLD'S FIRST VIDEO SYSTEM FOR RADIOTHERAPY, NOW FDA CLEARED AND IN USE CLINICALLY, TO DEVELOPED BEAMSITE-ULTRA, SPECIFICALLY FOR IMAGING FLASH. IN OUR PHASE I GRANT, WE SUCCESSFULLY DEMONSTRATED THE ABILITY TO IMAGE AT THE HIGH FRAME RATES AND TRANSFER SPEEDS NECESSARY TO CAPTURE A SINGLE BEAM PULSE ENERGY IN PHANTOMS AND ON TISSUE. IN THIS PHASE II, WE WILL ADVANCE BEAMSITE-ULTRA AS A ROBUST, MANUFACTURABLE, AND FDA CLEARABLE COMMERCIAL SYSTEM. WE WILL QUANTIFY BOTH SPATIAL AND TEMPORAL PULSE STRUCTURES, DEMONSTRATE BEAM-ON AND GATING-OFF POTENTIAL OF THE SYSTEM, AND ESTABLISH THE CAPABILITIES IN BOTH PROTON AND ELECTRON FLASH CLINICAL SETTINGS. THE WORK INCLUDES AN EXTENSIVE TEAM OF INDUSTRY AND ACADEMIC MEDICINE COLLEAGUES, USING THE EFLASH RESOURCES AT DARTMOUTH-HITCHCOCK MEDICAL CENTER AND THE PROTON TREATMENT FACILITIES AT THE UNIVERSITY OF KANSAS MEDICAL CENTER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 8/1/23 | ||
| Not listed | $1.0m | 9/21/22 | ||
| Not listed | $1.0m | 9/21/22 |